1,5-二(4-氰基苯氧基)戊烷 | 7467-71-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1,5-二(4-氰基苯氧基)戊烷
• 中文别名: [1,5-双(4-氰基苯酚)戊烷]
• 英文名称: 4-{[5-(4-cyanophenoxy)pentyl]oxy}benzonitrile
• 英文别名: 1,3-bis(4-cyanophenoxy)pentane；4,4′-(pentane-1,5-diylbis(oxy))dibenzonitrile；4,4'-pentanediyldioxy-di-benzonitrile；1.5-Bis-(4-cyan-phenoxy)-pentan；4,4'-pentamethylenedioxydibenzonitrile；4,4'-Pentandiyldioxy-di-benzonitril；4-[5-(4-cyanophenoxy)pentoxy]benzonitrile
• CAS: 7467-71-2
• 化学式: C₁₉H₁₈N₂O₂
• 分子量: 306.364
• InChiKey: DHTURPCVCDUKBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  66
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2926909090
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  1,5-二(4-氰基苯氧基)戊烷 在 盐酸 、 乙醇 、 肼 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 48.0h， 以81%的产率得到1,5-bis(benzamidrazone-4-oxy)pentane dihydrochloride
  参考文献：
  名称：

  Structure−Activity Study of Pentamidine Analogues as Antiprotozoal Agents

  摘要：

  Diamidine 1 (pentamidine) and 65 analogues (2-66) have been tested for in vitro antiprotozoal activities against Trypanosoma brucei rhodesiense, Plasmodium. falciparum, and Leishmania donovani, and for cytotoxicity against mammalian cells. Dications 32, 64, and 66 exhibited antitrypanosomal potencies equal or greater than melarsoprol (IC50 = 4 nM). Nine congeners (2-4, 12, 27, 30, and 64-66) were more active against P. falciparum than artemisinin (IC50 = 6 nM). Eight compounds (12, 32, 33, 44, 59, 62, 64, and 66) exhibited equal or better antileishmanial activities than 1 (IC50 = 1.8 mu M). Several congeners were more active than I in vivo, curing at least 2/4 infected animals in the acute mouse model of trypanosomiasis. The diimidazoline 66 was the most promising compound in the series, showing excellent in vitro activities and high selectivities against T. b. rhodesiense, P. falciparum, and L. donovani combined with high antitrypanosomal efficacy in vivo.

  DOI：

  10.1021/jm801547t
• 作为产物：
  描述：

  4-氰基乙酸苯酯 在 氢氧化钾 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 8.33h， 生成 1,5-二(4-氰基苯氧基)戊烷
  参考文献：
  名称：

  Nandi, Gopa; Mukherjee, S.; Basu, M. K., Journal of the Indian Chemical Society, 1993, vol. 70, # 6, p. 527 - 532

  摘要：

  DOI：

文献信息

• Discovery of decamidine as a new and potent PRMT1 inhibitor
  作者：Jing Zhang、Kun Qian、Chunli Yan、Maomao He、Brenson A. Jassim、Ivaylo Ivanov、Yujun George Zheng

  DOI：10.1039/c6md00573j

  日期：——

  This report presents the synthesis and evaluation of compound decamidine as a potent inhibitor for protein arginine methyltransferase 1 (PRMT1).

  这份报告介绍了十甲胺作为蛋白质精氨酸甲基转移酶1（PRMT1）的有效抑制剂的合成和评价。
• ARYL DIAMIDINES AND PRODRUGS THEREOF FOR TREATING MYOTONIC DYSTROPHY
  申请人：Education, on behalf of the University of Oregon State of Oregon, acting by and through the State Board of Higher

  公开号：US20130281462A1

  公开（公告）日：2013-10-24

  Disclosed herein are compounds (for example, diamidine derivatives and prodrugs) and methods of use thereof, for example in treating muscular dystrophy (DM) or disease caused by a toxic RNA in a subject. In some embodiments, the methods include administering an effective amount of one of more of the disclosed compounds to a subject to treat or inhibit DM or a disease caused by or associated with toxic RNA, such as DM1, DM2, spinocerebellar ataxia type 8 (SCA8), fragile X tremor ataxia syndrome (FXTAS), or Huntington disease-like 2 (HLD2). In some examples, the methods include selecting a subject for treatment, for example selecting a subject with DM1, DM2, SCA8, FXTAS, or HLD2.

  本文披露了化合物（例如，二胺衍生物和前药）及其使用方法，例如用于治疗肌肉萎缩症（DM）或由有毒RNA引起的疾病。在某些实施例中，该方法包括向受试者施用所披露化合物中的一个或多个的有效量，以治疗或抑制DM或由有毒RNA引起或与之相关的疾病，如DM1、DM2、脊髓小脑共济失调8型（SCA8）、脆性X颤动共济失调综合征（FXTAS）或亨廷顿病样2型（HLD2）。在某些示例中，该方法包括选择受试者进行治疗，例如选择患有DM1、DM2、SCA8、FXTAS或HLD2的受试者。
• Structure–Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens
  作者：Charlotte M. J. Wesseling、Cornelis J. Slingerland、Shanice Veraar、Samantha Lok、Nathaniel I. Martin

  DOI：10.1021/acsinfecdis.1c00466

  日期：2021.12.10

  observed synergistic activity reported for pentamidine, while further assessing the capacity for structurally similar bis-amidines to also potentiate Gram-positive specific antibiotics against Gram-negative pathogens. Among the bis-amidines prepared, a number of them were found to exhibit synergistic activity greater than pentamidine. These synergists were shown to effectively potentiate the activity of

  喷他脒是一种 FDA 批准的抗寄生虫药，最近被鉴定为一种外膜破坏增效剂，可增强红霉素、利福平和新生霉素对革兰氏阴性菌的作用。同一项研究还描述了使用市售喷他脒类似物的初步构效关系。我们在这里报告了受喷他脒启发的更广泛的双脒组的设计、合成和评估。本研究既验证了先前观察到的喷他脒的协同活性，同时进一步评估了结构相似的双脒增强革兰氏阳性特异性抗生素对抗革兰氏阴性病原体的能力。在制备的双脒中，发现其中一些表现出比喷他脒更大的协同活性。鲍曼不动杆菌、肺炎克雷伯菌、铜绿假单胞菌和大肠杆菌，包括耐多粘菌素和碳青霉烯的菌株。
• DNA Sequence-Specific Ligands: XII. Synthesis and Cytological Studies of Dimeric Hoechst 33258 Molecules
  作者：A. V. Gromyko、K. V. Popov、A. P. Mosoleva、S. A. Streltsov、S. L. Grokhovsky、V. A. Oleinikov、A. L. Zhuze

  DOI：10.1007/s11171-005-0047-z

  日期：2005.7

  We synthesized dimeric Hoechst dye molecules composed of two moieties of the Hoechst 33258 fluorescent dye phenolic hydroxy groups of which were tethered via pentamethylene, heptamethylene, or triethylene oxide linkers. A characteristic pattern of differential staining of chromosome preparations from human premonocytic leukemia HL60 cells was observed for all the three fluorescent dyes. The most contrast

  我们合成了由两个部分的Hoechst 33258荧光染料酚羟基组成的二聚体Hoechst染料分子，这些分子通过五亚甲基，七亚甲基或三环氧乙烷接头进行束缚。对于所有三种荧光染料，观察到来自人单核细胞白血病HL60细胞的染色体制剂的差异染色的特征性模式。对于具有七亚甲基接头的bis-Hoechst类似物，获得了最大的对比图样；其质量与用4'，6-二mid基-2-苯基吲哚进行染色体染色时获得的图像相当。研究了三种bis-Hoechst化合物对人体成纤维细胞的渗透能力。发现被五戊二烯和庚二烯键联的双-Hoechst类似物染色的活细胞和固定细胞核的荧光强度仅略有不同，而被三环氧乙烷-键合的双-Hoechst染色的活细胞的核荧光却相当大。比固定细胞弱。bis-Hoechst分子是新型的有前途的荧光染料，既可以对染色体制备物进行差异染色，也可以穿透细胞和核膜，并有效地染色细胞核。
• Amidine derivatives for treating amyloidosis
  申请人：Neurochem, Inc.

  公开号：US20040006092A1

  公开（公告）日：2004-01-08

  The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited: 1

  本发明涉及在治疗与淀粉样蛋白相关的疾病中使用脲类化合物。特别地，本发明涉及一种治疗或预防受试者淀粉样蛋白相关疾病的方法，包括向受试者施用治疗量的脲类化合物。本发明中可用的化合物包括以下公式的化合物，当施用时，可减少或抑制淀粉样蛋白纤维形成、神经退行性或细胞毒性：1